Biography

Dr. Liang Fu is a pulmonologist and tuberculosis specialist at Shenzhen Third People's Hospital. He holds a Master's degree in Respiratory Medicine from Southern Medical University and a Ph.D. in Tuberculosis from Capital Medical University. Since 2008, Dr. Fu has been engaged in the diagnosis, treatment, and research of respiratory diseases and tuberculosis, with expertise in MDR-TB and NTM. He is a member of the National Health Commission's "Global Health Talent Reserve" and has contributed to national tuberculosis clinical research projects. Dr. Fu has published extensively in leading medical journals and serves on several academic committees.

Expertise

TB Diagnostics
Public Health

Key Impacts

Long-term survival and prognostic determinants of tuberculous meningitis in a high-migration metropolis: A decade-long bidirectional cohort study

A decade-long study in Shenzhen, China, reveals that tuberculous meningitis mortality can be reduced to <10% in high-migration megacities through early intensive care and staged surgery, particularly in HIV-positive patients.

Source: Conference 2024
QTcF prolongation associated with bedaquiline-delamanid-linezolid regimens containing levofloxacin or moxifloxacin: A multicentre retrospective cohort study in rifampicin-resistant TB

Addition of Lfx or Mfx to the BDL regimen did not significantly increase the risk of QTcF prolongation or severe arrhythmias. A slightly better profile was observed for Lfx, though the sample size was small. QTcF prolongation was mainly associated with underlying comorbidities, underscoring the importance of risk stratification and ECG monitoring in vulnerable populations. Further studies are warranted to clarify cardiac safety differences among regimens.

Source: Conference 2024
Breath analysis using HPPI-TOF-MS and spatial attention convolutional neural networks for latent TB infection screening: A diagnostic accuracy study

The developed spatial attention CNN effectively addresses data drift, identifies key biomarkers, and accurately classifies TB stages, supporting breath-based LTBI screening. Future validation in community settings is needed to confirm practical applicability.

Source: Conference 2024
Transforming TB treatment monitoring with breathomics: A prospective cohort study in drug-susceptible pulmonary TB

Our dual-model framework, integrating breath-based Transformer and MLP models, enables non-invasive tracking of TB recovery and identifies patients likely to achieve favorable outcomes before 6 months. These findings support the potential of breathomics-guided tools for individualized treatment shortening, warranting prospective clinical validation in real-world settings.

Source: Conference 2024

Research Summaries